Company news

OncoSil Medical Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Regulatory Application Filed for Australian Manufacturing

November 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Annual Report (Typeset)

October 26, 2026

Peer-Reviewed Study Reports 100% Disease Control

October 26, 2026

Change of Director's Interest Notice

October 26, 2026

Notification of cessation of securities - OSL

October 26, 2026

Updated OSPREY Overall Survival Data Presented at EAMN

October 20, 2026

Notice of Annual General Meeting/Proxy Form

October 18, 2026

Application for quotation of securities - OSL

October 15, 2026

PALACROS Officially Launched in Amsterdam

October 12, 2026

OncoSil Clinical Data to be Presented at EANM 2026

September 29, 2026

Notice of AGM date

September 27, 2026

Notice under ASX Listing Rule 3.10A

September 14, 2026

Change in substantial holding

September 14, 2026

Change in substantial shareholding for OSL

September 13, 2026

Notice Under Section 708A

September 9, 2026

Application for quotation of securities - OSL

September 9, 2026

Application for quotation of securities - OSL

September 9, 2026

Australian Manufacturing Facility Achieves ISO 13485

September 8, 2026

100th Patient Treated with OncoSil device in Spain

September 7, 2026

OSL Secures $5.6 million from Major Institutional Investors

September 7, 2026

Proposed issue of securities - OSL

September 7, 2026

OncoSil submits US Reimbursement Application (Updated)

September 1, 2026

OncoSil submits US Reimbursement Application

September 1, 2026

Appendix 4G and Corporate Governance Statement

August 28, 2026

Appendix 4E and Annual Report

August 28, 2026

Change in substantial holding

August 21, 2026

Change in substantial shareholding for OSL

August 19, 2026

Application for quotation of securities - OSL

August 17, 2026

Investor Webinar Presentation

August 17, 2026

OncoSil Receives FDA Approval for Distal Cholangiocarcinoma

August 16, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 29, 2026

OncoSil Medical Completes Manufacturing Validation

July 12, 2026

OncoSil Medical Files for FDA Approval

July 2, 2026

OncoSil Selected for Major European Pancreatic Cancer Study

July 1, 2026

OncoSil progresses HDE with US FDA

June 8, 2026

OncoSil Medical Receives TGA Approval in Australia

May 19, 2026

Security Class Reinstatement to Quotation - OSLOE

March 17, 2026

Security Class Suspension from Quotation

March 10, 2026

Appendix 4D and Half Year Accounts

February 23, 2026

CEO Remuneration Update

February 11, 2026

Capital Raising Presentation

February 3, 2026

Prospectus

February 3, 2026

$8.0 million Capital Raise for Ongoing Commercial Expansion

February 3, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Trading Halt

January 29, 2026

OncoSil receives $1.84m R&D tax incentive

January 7, 2026

OSPREY Analysis Shows Survival Benefit for OncoSil Patients

December 2, 2025

Response to ASX Aware Letter

September 29, 2025

Older news releases →

Decks

The 5 newest of 41 decks. Every deck is listed under its year.